Usona Institute Clinical Trial of Psilocybin for Major Depressive Disorder Launching This Fall
September 05, 2019 09:03 AM Eastern Daylight Time
MADISON, Wis.–(BUSINESS WIRE)–Usona Institute launches its Phase 2 study of psilocybin for major depressive disorder this fall. The study, PSIL201, will be conducted at seven U.S. sites and will investigate the safety and efficacy of psilocybin for major depressive disorder (MDD). The open dates for the trial will vary by site, with the first sites scheduled to begin enrolling participants within the next two months.
